{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:27:20Z","timestamp":1789964840242,"version":"4.0.1"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"MEDGENET, Medical Genomics and Epigenomics Network","award":["692298"],"award-info":[{"award-number":["692298"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.semcancer.2016.07.005","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T22:34:13Z","timestamp":1470177253000},"page":"40-48","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["NF-\u03baB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions"],"prefix":"10.1016","volume":"39","author":[{"given":"Larry","family":"Mansouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikos","family":"Papakonstantinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavroula","family":"Ntoufa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rosenquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7203","key":"10.1016\/j.semcancer.2016.07.005_bib0005","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.semcancer.2016.07.005_bib0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.semcancer.2016.07.005_bib0015","doi-asserted-by":"crossref","first-page":"a000109","DOI":"10.1101\/cshperspect.a000109","article-title":"Oncogenic activation of NF-kappaB","volume":"2","author":"Staudt","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"7354","key":"10.1016\/j.semcancer.2016.07.005_bib0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.semcancer.2016.07.005_bib0025","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2011-12-395673","article-title":"Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia","volume":"119","author":"Rossi","year":"2012","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2016.07.005_bib0030","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1084\/jem.20142009","article-title":"Functional loss of IkappaBepsilon leads to NF-kappaB deregulation in aggressive chronic lymphocytic leukemia","volume":"212","author":"Mansouri","year":"2015","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2016.07.005_bib0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4161\/epi.23439","article-title":"Uncovering the DNA methylome in chronic lymphocytic leukemia","volume":"8","author":"Cahill","year":"2013","journal-title":"Epigenetics"},{"issue":"6","key":"10.1016\/j.semcancer.2016.07.005_bib0040","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.semcancer.2013.09.001","article-title":"B-cell receptor signaling as a driver of lymphoma development and evolution","volume":"23","author":"Niemann","year":"2013","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.semcancer.2016.07.005_bib0045","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1084\/jem.2126insight4","article-title":"Augmenting NF-kappaB in poor-risk CLL: a general paradigm for other cancers?","volume":"212","author":"Tuveson","year":"2015","journal-title":"J. Exp. Med."},{"issue":"8","key":"10.1016\/j.semcancer.2016.07.005_bib0050","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/ni.2065","article-title":"Crosstalk in NF-kappaB signaling pathways","volume":"12","author":"Oeckinghaus","year":"2011","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.semcancer.2016.07.005_bib0055","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00018-013-1545-4","article-title":"NF-kappaB pathways in hematological malignancies","volume":"71","author":"Gasparini","year":"2014","journal-title":"Cell. Mol. Life Sci."},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0060","doi-asserted-by":"crossref","first-page":"a000034","DOI":"10.1101\/cshperspect.a000034","article-title":"The NF-kappaB family of transcription factors and its regulation","volume":"1","author":"Oeckinghaus","year":"2009","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-065X.2011.01088.x","article-title":"The noncanonical NF-kappaB pathway","volume":"246","author":"Sun","year":"2012","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0070","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.4049\/jimmunol.164.4.2200","article-title":"Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells","volume":"164","author":"Furman","year":"2000","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.semcancer.2016.07.005_bib0075","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/sj.leu.2403398","article-title":"A sustained activation of PI3K\/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells","volume":"18","author":"Cuni","year":"2004","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.semcancer.2016.07.005_bib0080","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1182\/blood-2007-11-125278","article-title":"The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target","volume":"111","author":"Hewamana","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1158\/1541-7786.MCR-10-0559","article-title":"STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells","volume":"9","author":"Liu","year":"2011","journal-title":"Mol. Cancer Res."},{"issue":"6","key":"10.1016\/j.semcancer.2016.07.005_bib0090","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","article-title":"The B-cell receptor signaling pathway as a therapeutic target in CLL","volume":"120","author":"Woyach","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00109-013-1081-6","article-title":"RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow","volume":"92","author":"Xu","year":"2014","journal-title":"J. Mol. Med. Berl."},{"issue":"2","key":"10.1016\/j.semcancer.2016.07.005_bib0100","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","article-title":"The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia","volume":"117","author":"Herishanu","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semcancer.2016.07.005_bib0105","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2141.1989.tb04290.x","article-title":"Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro","volume":"71","author":"Collins","year":"1989","journal-title":"Br. J. Haematol."},{"issue":"12","key":"10.1016\/j.semcancer.2016.07.005_bib0110","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2003-12-4312","article-title":"Chronic lymphocytic leukemia: revelations from the B-cell receptor","volume":"103","author":"Stevenson","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcancer.2016.07.005_bib0115","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.semcancer.2010.09.004","article-title":"Antigens in chronic lymphocytic leukemia\u2013implications for cell origin and leukemogenesis","volume":"20","author":"Rosen","year":"2010","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"10.1016\/j.semcancer.2016.07.005_bib0120","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.semcancer.2013.07.006","article-title":"Antigen selection in B-cell lymphomas\u2013tracing the evidence","volume":"23","author":"Sutton","year":"2013","journal-title":"Semin. Cancer Biol."},{"issue":"16","key":"10.1016\/j.semcancer.2016.07.005_bib0125","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1158\/0008-5472.CAN-14-0630","article-title":"Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution","volume":"74","author":"Vardi","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.semcancer.2016.07.005_bib0130","first-page":"453","article-title":"The history of toll-like receptors\u2014redefining innate immunity","volume":"13","author":"O'Neill","year":"2013","journal-title":"Nat. Rev."},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0135","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2008.07475.x","article-title":"Expression and function of toll like receptors in chronic lymphocytic leukaemia cells","volume":"144","author":"Muzio","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.semcancer.2016.07.005_bib0140","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.3324\/haematol.2011.044792","article-title":"Toll-like receptor signaling pathway in chronic lymphocytic leukemia: distinct gene expression profiles of potential pathogenic significance in specific subsets of patients","volume":"96","author":"Arvaniti","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2016.07.005_bib0145","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2119\/molmed.2011.00480","article-title":"Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors","volume":"18","author":"Ntoufa","year":"2012","journal-title":"Mol. Med."},{"issue":"12","key":"10.1016\/j.semcancer.2016.07.005_bib0150","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.it.2013.07.002","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger","year":"2013","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.semcancer.2016.07.005_bib0155","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1172\/JCI200522094","article-title":"Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis","volume":"115","author":"Contri","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"13","key":"10.1016\/j.semcancer.2016.07.005_bib0160","doi-asserted-by":"crossref","first-page":"5424","DOI":"10.1158\/0008-5472.CAN-08-4252","article-title":"Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia","volume":"69","author":"Buchner","year":"2009","journal-title":"Cancer Res."},{"issue":"23","key":"10.1016\/j.semcancer.2016.07.005_bib0165","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","article-title":"Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.semcancer.2016.07.005_bib0170","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1182\/blood-2002-02-0539","article-title":"Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cdelta","volume":"100","author":"Ringshausen","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0175","doi-asserted-by":"crossref","first-page":"e2012055","DOI":"10.4084\/mjhid.2012.055","article-title":"Toll-like receptors in chronic lymphocytic leukemia","volume":"4","author":"Muzio","year":"2012","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"issue":"6325","key":"10.1016\/j.semcancer.2016.07.005_bib0180","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/351355b0","article-title":"Drosophila toll and IL-1 receptor","volume":"351","author":"Gay","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2016.07.005_bib0185","first-page":"1","article-title":"TLR signaling","volume":"311","author":"Akira","year":"2006","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0190","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smim.2003.10.003","article-title":"TLR signaling pathways","volume":"16","author":"Takeda","year":"2004","journal-title":"Semin. Immunol."},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0195","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nri3190","article-title":"Integration of B cell responses through Toll-like receptors and antigen receptors","volume":"12","author":"Rawlings","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.semcancer.2016.07.005_bib0200","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3389\/fimmu.2014.00461","article-title":"Toll-like receptor signaling pathways","volume":"5","author":"Kawasaki","year":"2014","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.semcancer.2016.07.005_bib0205","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1182\/blood.V95.3.999.003k10_999_1006","article-title":"Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells","volume":"95","author":"Decker","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0210","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1189\/jlb.69.1.81","article-title":"CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens","volume":"69","author":"Jahrsdorfer","year":"2001","journal-title":"J. Leukoc. Biol."},{"issue":"3","key":"10.1016\/j.semcancer.2016.07.005_bib0215","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1189\/jlb.0604373","article-title":"Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells","volume":"77","author":"Jahrsdorfer","year":"2005","journal-title":"J. Leukoc. Biol."},{"issue":"24","key":"10.1016\/j.semcancer.2016.07.005_bib0220","doi-asserted-by":"crossref","first-page":"5041","DOI":"10.1182\/blood-2009-03-213363","article-title":"Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells","volume":"115","author":"Liang","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.semcancer.2016.07.005_bib0225","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.4049\/jimmunol.1502297","article-title":"B cell anergy modulated by TLR1\/2 and the miR-17 approximately 92 cluster underlies the indolent clinical course of chronic lymphocytic leukemia stereotyped subset #4","volume":"196","author":"Ntoufa","year":"2016","journal-title":"J. Immunol."},{"issue":"24","key":"10.1016\/j.semcancer.2016.07.005_bib0230","doi-asserted-by":"crossref","first-page":"3790","DOI":"10.1182\/blood-2013-12-543306","article-title":"Mutations in TLR\/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome","volume":"123","author":"Martinez-Trillos","year":"2014","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.semcancer.2016.07.005_bib0235","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1109016","article-title":"SF3B1 and other novel cancer genes in chronic lymphocytic leukemia","volume":"365","author":"Wang","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.semcancer.2016.07.005_bib0245","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/annonc\/mdh213","article-title":"CD40 activation: potential for specific immunotherapy in B-CLL","volume":"15","author":"von Bergwelt-Baildon","year":"2004","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.semcancer.2016.07.005_bib0250","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/ni.1676","article-title":"Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK","volume":"9","author":"Zarnegar","year":"2008","journal-title":"Nat. Immunol."},{"issue":"12","key":"10.1016\/j.semcancer.2016.07.005_bib0255","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/ni.1678","article-title":"Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling","volume":"9","author":"Vallabhapurapu","year":"2008","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.semcancer.2016.07.005_bib0260","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood.V92.3.990","article-title":"Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells","volume":"92","author":"Romano","year":"1998","journal-title":"Blood"},{"issue":"5-6","key":"10.1016\/j.semcancer.2016.07.005_bib0265","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3109\/10428190009058499","article-title":"CD40 ligand in CLL pathogenesis and therapy","volume":"37","author":"Schattner","year":"2000","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.semcancer.2016.07.005_bib0270","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/leu.2013.333","article-title":"On the way towards a \u2018CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort","volume":"28","author":"Cortese","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.semcancer.2016.07.005_bib0275","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.3109\/10428194.2014.898760","article-title":"NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment","volume":"55","author":"Chiaretti","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"2","key":"10.1016\/j.semcancer.2016.07.005_bib0280","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/leu.2014.196","article-title":"Recurrent mutations refine prognosis in chronic lymphocytic leukemia","volume":"29","author":"Baliakas","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.semcancer.2016.07.005_bib0285","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3324\/haematol.2012.069369","article-title":"Clinical implications of the molecular genetics of chronic lymphocytic leukemia","volume":"98","author":"Foa","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.semcancer.2016.07.005_bib0290","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","article-title":"Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia","volume":"121","author":"Rossi","year":"2013","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.semcancer.2016.07.005_bib0295","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bjh.13254","article-title":"The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications","volume":"169","author":"Strefford","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0305","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3324\/haematol.2013.098574","article-title":"ATM mutation rather than BIRC3 deletion and\/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial","volume":"99","author":"Rose-Zerilli","year":"2014","journal-title":"Haematologica"},{"issue":"7332","key":"10.1016\/j.semcancer.2016.07.005_bib0310","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.semcancer.2016.07.005_bib0315","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00401-011-0891-2","article-title":"Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma","volume":"122","author":"Montesinos-Rongen","year":"2011","journal-title":"Acta Neuropathol."},{"issue":"9","key":"10.1016\/j.semcancer.2016.07.005_bib0320","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.semcancer.2016.07.005_bib0325","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0330","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2015-01-620518","article-title":"High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates","volume":"126","author":"Bonzheim","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.semcancer.2016.07.005_bib0335","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood-2008-07-170415","article-title":"High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation","volume":"113","author":"Burger","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semcancer.2016.07.005_bib0340","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1182\/blood-2015-05-648634","article-title":"Prognostic relevance of MYD88 mutations in CLL: the jury is still out","volume":"126","author":"Baliakas","year":"2015","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semcancer.2016.07.005_bib0345","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1158\/2159-8290.CD-14-0104","article-title":"Acquired initiating mutations in early hematopoietic cells of CLL patients","volume":"4","author":"Damm","year":"2014","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.semcancer.2016.07.005_bib0350","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.trecan.2016.02.005","article-title":"Novel mechanisms of regulation of miRNAs in CLL","volume":"2","author":"Balatti","year":"2016","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.semcancer.2016.07.005_bib0355","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jmcb\/mjr007","article-title":"MicroRNAs in NF-kappaB signaling","volume":"3","author":"Ma","year":"2011","journal-title":"J. Mol. Cell Biol."},{"key":"10.1016\/j.semcancer.2016.07.005_bib0360","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-kappaB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2016.07.005_bib0365","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1741-7007-11-19","article-title":"A functional genomics screen for microRNA regulators of NF-kappaB signaling","volume":"11","author":"Olarerin-George","year":"2013","journal-title":"BMC Biol."},{"issue":"15","key":"10.1016\/j.semcancer.2016.07.005_bib0370","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1158\/0008-5472.CAN-12-0803","article-title":"Extensive promoter DNA hypermethylation and hypomethylation is associated with aberrant microRNA expression in chronic lymphocytic leukemia","volume":"72","author":"Baer","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2016.07.005_bib0375","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/1476-4598-12-173","article-title":"Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia-implications on constitutive activation of NFkappaB pathway","volume":"12","author":"Wang","year":"2013","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.semcancer.2016.07.005_bib0380","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/ijc.29491","article-title":"Epigenetic silencing of miR-708 enhances NF-kappaB signaling in chronic lymphocytic leukemia","volume":"137","author":"Baer","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"50","key":"10.1016\/j.semcancer.2016.07.005_bib0385","doi-asserted-by":"crossref","first-page":"19643","DOI":"10.1073\/pnas.0810965105","article-title":"Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL","volume":"105","author":"Pekarsky","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0390","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/gcc.1099","article-title":"TCL1 is activated by chromosomal rearrangement or by hypomethylation","volume":"30","author":"Yuille","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"issue":"2","key":"10.1016\/j.semcancer.2016.07.005_bib0395","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2009-07-232868","article-title":"Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia","volume":"115","author":"Kanduri","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0400","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/ijc.11122","article-title":"Leucine-zipper protein, LDOC1, inhibits NF-kappaB activation and sensitizes pancreatic cancer cells to apoptosis","volume":"105","author":"Nagasaki","year":"2003","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0405","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/leu.2012.245","article-title":"450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments","volume":"27","author":"Cahill","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.semcancer.2016.07.005_bib0410","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1073\/pnas.102181599","article-title":"Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression","volume":"99","author":"Bichi","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"21","key":"10.1016\/j.semcancer.2016.07.005_bib0415","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2013-02-486035","article-title":"A sleeping beauty screen reveals NF-kB activation in CLL mouse model","volume":"121","author":"Zanesi","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0420","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1097-2765(00)80244-0","article-title":"TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway","volume":"5","author":"Takaesu","year":"2000","journal-title":"Mol. Cell"},{"issue":"33","key":"10.1016\/j.semcancer.2016.07.005_bib0425","doi-asserted-by":"crossref","first-page":"29973","DOI":"10.1074\/jbc.M203636200","article-title":"Inhibition of JNK by cellular stress- and tumor necrosis factor alpha-induced AKT2 through activation of the NF kappa B pathway in human epithelial Cells","volume":"277","author":"Yuan","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"47","key":"10.1016\/j.semcancer.2016.07.005_bib0430","doi-asserted-by":"crossref","first-page":"16600","DOI":"10.1073\/pnas.0407541101","article-title":"TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma\/chronic lymphocytic leukemia in transgenic mice","volume":"101","author":"Zapata","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.semcancer.2016.07.005_bib0435","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/jcb.21147","article-title":"Animal models for chronic lymphocytic leukemia","volume":"100","author":"Pekarsky","year":"2007","journal-title":"J. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0440","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.ccr.2004.08.033","article-title":"APRIL promotes B-1 cell-associated neoplasm","volume":"6","author":"Planelles","year":"2004","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.semcancer.2016.07.005_bib0445","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1158\/1078-0432.CCR-08-2382","article-title":"p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541","volume":"15","author":"Lopez-Guerra","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2016.07.005_bib0450","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1038\/bcj.2011.9","article-title":"The novel NF-kappaB inhibitor IMD-0354 induces apoptosis in chronic lymphocytic leukemia","volume":"1","author":"Kanduri","year":"2011","journal-title":"Blood Cancer J."},{"issue":"19","key":"10.1016\/j.semcancer.2016.07.005_bib0455","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1158\/1078-0432.CCR-05-2501","article-title":"MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo","volume":"12","author":"Hideshima","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.semcancer.2016.07.005_bib0460","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1182\/blood.V96.7.2537.h8002537_2537_2542","article-title":"Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells","volume":"96","author":"Keller","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semcancer.2016.07.005_bib0465","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1182\/blood-2002-01-0151","article-title":"Bay 11-7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells","volume":"100","author":"Mori","year":"2002","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semcancer.2016.07.005_bib0470","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.leukres.2005.05.004","article-title":"Inhibition of NF-kappaB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines","volume":"29","author":"Garcia","year":"2005","journal-title":"Leuk. Res."},{"issue":"5","key":"10.1016\/j.semcancer.2016.07.005_bib0475","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/cncr.22097","article-title":"Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia","volume":"107","author":"Faderl","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0480","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1182\/blood.V92.4.1406","article-title":"Aspirin and salicylate induce apoptosis and activation of caspases in B-cell chronic lymphocytic leukemia cells","volume":"92","author":"Bellosillo","year":"1998","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.semcancer.2016.07.005_bib0485","first-page":"5711","article-title":"Benzylamide sulindac analogues induce changes in cell shape, loss of microtubules and G(2)-M arrest in a chronic lymphocytic leukemia (CLL) cell line and apoptosis in primary CLL cells","volume":"62","author":"Moon","year":"2002","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0490","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/ajh.20757","article-title":"Preclinical assessment of curcumin as a potential therapy for B-CLL","volume":"82","author":"Everett","year":"2007","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0495","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1517\/14728220903431069","article-title":"The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy","volume":"14","author":"Lin","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"issue":"9","key":"10.1016\/j.semcancer.2016.07.005_bib0500","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-10-2879","article-title":"Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia","volume":"17","author":"Amrein","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.semcancer.2016.07.005_bib0505","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.semcancer.2016.07.005_bib0510","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","article-title":"An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia","volume":"125","author":"Sharman","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcancer.2016.07.005_bib0515","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","article-title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","volume":"369","author":"Byrd","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"16","key":"10.1016\/j.semcancer.2016.07.005_bib0520","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semcancer.2016.07.005_bib0525","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3324\/haematol.2014.119123","article-title":"The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia","volume":"100","author":"Wiestner","year":"2015","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.semcancer.2016.07.005_bib0530","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.semcancer.2016.07.005_bib0535","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X16300311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X16300311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T13:09:49Z","timestamp":1692450589000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X16300311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":107,"alternative-id":["S1044579X16300311"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2016.07.005","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NF-\u03baB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2016.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}